On February 11, the FDA authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply:
- They have a positive COVID-19 test result
- They’re at high-risk for progression to severe COVID-19
- Alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically appropriate for them
CMS created new codes, effective February 11:
Q0222:
- Long descriptor: Injection, bebtelovimab, 175 mg
- Short descriptor: Bebtelovimab 175
M0222:
- Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring
- Short Descriptor: Bebtelovimab injection
M0223:
- Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
- Short Descriptor: Bebtelovimab injection home